Diana Heimhalt considers the current approach to assessing the added therapeutic value of new medicines, and outlines some of the perceived benefits and possible complexities of a harmonised EU approach.
A legal toolkit for life sciences companies and their investors providing access to information on:
Samantha Bennett discusses the report of the annual joint conference of the BIA and the MHRA, which advocates putting patients at the centre of drug development...read more
Anja Lunze explains the significance of the District Court of Hamburg's first instance decision relating to second medical use patents...read more
Our lawyers in Germany, Austria and the Netherlands, highlight the complex sector-specific issues in their jurisdictions...read more
Receive our monthly newsletter keeping you updated on recent developments and events in the Life Sciences sector...